ArticleThe journal of nutrition, health & aging2026
Sarcopenia and recurrence risk in high-risk non-muscle-invasive bladder cancer: a nonlinear modeling approach.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation.Translational andrology and urology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSarcopenia and altered body composition are established prognostic markers in several malignancies, but their relevance in non-muscle-invasive bladder cancer (NMIBC) remains unclear. This study evaluated associations between body composition indices-body mass index (BMI), skeletal muscle index (SMI), and psoas muscle index (PMI)-and recurrence risk in high-risk NMIBC patients treated with intravesical Bacillus Calmette-Guérin (BCG).
methodsBody composition was assessed on computed tomography at primary diagnosis. Sarcopenia was defined using published sex-specific cut-offs. Recurrence-free survival (RFS) was analyzed using Kaplan-Meier estimates, Cox regression with linear and spline terms, and a gradient boosted machine (GBM) model.
resultsA total of 118 patients (median age 71 years; 78% male) were included. Tumor stages were pTa (40%), pT1 (54%), and primary carcinoma in situ (CIS) in 6%. During a mean follow-up of 32 months, 30 patients (25.4%) developed recurrence. Median BMI was 26 kg/m². SMI and PMI were higher in men and declined with age, whereas BMI remained stable. Sarcopenia prevalence varied widely across definitions (6-66%) with low-to-moderate concordance (Cohen's κ: 0-0.58). No sarcopenia definition independently predicted recurrence. In the GBM model, BCG maintenance, tumor stage, CIS, age, BMI, SMI, and PMI were important predictors. Spline Cox models demonstrated nonlinear U-shaped associations between BMI, SMI, PMI, and recurrence risk, with increased risk at both low and high values.
conclusionsBody composition shows nonlinear associations with recurrence in high-risk NMIBC. Both low and excessive body and muscle mass may adversely affect disease control. The heterogeneity and limited prognostic value of current sarcopenia definitions highlight the need for standardized, multiparametric, and nonlinear risk modeling approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.